Browse > Article

Synthesis of New Benzylpiperidinyl Ether Derivatives as Amyloid-beta Aggregation Inhibitors  

Kwon, Young-Ee (College of Pharmacy, Woosuk University)
Publication Information
YAKHAK HOEJI / v.50, no.5, 2006 , pp. 326-331 More about this Journal
Abstract
We designed and synthesized new benzylpiperidinyl ether derivatives as beta-amyloid aggregation inhibitors for the development of novel anti-Alzheimer's disease agents. As starting material, 4-hydroxypiperidine was used. For protection of the amine group in piperidine (2), di-tert-butyl dicarbonate was reacted with 4-hydroxypiperidine in the presence of triethylamine. For introduction of benzyl group, benzylbromide was treated with compound 2 in dioxane. After deprotection of Boc group on amine in compound 3, ester (5) was synthesized by addition of ethyl-4-chlorobutyrate. The alcohol 6 was synthesized by hydride reduction of 5 using $LiAlH_4$. To obtain final products (7-14), the alcohol 6 was condensed with each of substituted benzoic acids. To screen beta-amyloid aggregation inhibition of the products, thioflavinT assay was performed using $A{\beta}1-42\;at\;37^{\circ}C$ for 26 h incubation, in vitro. From the result of screening, compound 8, 9, 11 and 12 showed effective activity about $65{\sim}85\;{\mu}M\;as\;IC_{50}$ value. Among the prepared compounds, 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate (8) was the most effective inhibitor having $IC_{50}\;of\;65.4{\mu}M$.
Keywords
Amyloid-beta aggregation inhibitor; Alzheimer's disease; piperidine derivatives; $A{\beta}1-42$;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Khachaturian, Z. S. : Diagnosis of Alzhemier's disease. Arch. Neurol. 42, 1097 (1985)   DOI   ScienceOn
2 Cottingham, M. G., Voskuil, J. L. and Vaux, D. J. : The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry 42, 10863 (2003)   DOI   ScienceOn
3 Prous, J., Rabasseda, X. and Castaner, J. : SDZ-ENA-713 cognition enhancer acetylcholinesterase inhibitor. Drugs Future 19, 656 (1996)
4 De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I. and Inestrosa, N. C. : A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 40, 10447 (2001)   DOI   ScienceOn
5 Sugimoto, H. : Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. 1, 63 (2001)   DOI   ScienceOn
6 Barril, X., Orozco, M. and Luque, F. J. : Towards improved acetylcholinesterase inhibitors: a structural and computational approach. Mini. Rev. Med. Chem. 1, 255 (2001)   DOI   ScienceOn
7 Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D. and Riek, R. : 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA 102, 17342 (2005)
8 Massi, F. and Straub, J. E. : Structural and dynamical analysis of the hydration of the Alzheimer's beta-amyloid peptide. J. Comput. Chem. 24, 143 (2003)   DOI   ScienceOn
9 Santini, S., Mousseau, N. and Derreumaux, P. : In silico assembly of Alzheimer's Abeta16-22 peptide into beta-sheets. J. Am. Chem. Soc. 126, 11509 (2004)   DOI   ScienceOn
10 Greig, N. H., Sambamurti, K., Yu, Q. S., Brossi, A., Bruinsma, G. B. and Lahiri, D. K. : An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. 2, 281 (2005)   DOI   ScienceOn
11 Selkoe, D. J. : Translating cell biology into therapeutic advances in Alzhemier's disease. Nature 399, A23 (1999)   DOI   ScienceOn
12 Lilienfeld, S. : Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8, 159 (2002)   DOI   ScienceOn
13 Kurz, A. : The therapeutic potential of tacrine. J. Neural Transm. Suppl. 54, 295 (1998)
14 Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F. and Tycko, R. : A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints fromsolid state NMR. Proc. Natl. Acad. Sci. USA 99, 16742 (2002)
15 Patrice, T. : $\beta$-Amyloid aggregation inhibitors for Treatment of Alzheimer's disease: Dream or Reality- Mini Reviews in Medicinal Chemistry 1, 175 (2001)   DOI   ScienceOn
16 Clarimon, J., Bertranpetit, J., Calafell, F., Boada, M., Tarraga, L. and Comas, D. : Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1. J. Neurol. 250, 956 (2003)   DOI   ScienceOn
17 Pietrzik, C. and Behl, C. : Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. 86, 173 (2005)   DOI   ScienceOn
18 Silverberg, G. D., Mayo, M., Saul, T., Carvalho, J. and McGuire, D. : Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert. Rev. Neurother. 4, 97 (2004)   DOI   ScienceOn
19 Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A. and Klein, W. L. : Alzheimer's disease-affected brain: presence of oligomeric A-beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417 (2003)
20 Cottingham, M. G., Hollinshead, M. S. and Vaux, D. J. : Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry 41, 13539 (2002)   DOI   ScienceOn
21 Jann, M. W. : Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20, 1 (2000)   DOI   ScienceOn
22 Zarotsky, V., Sramek, J. J. and Cutler, N. R. : Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60, 446 (2003)
23 Hollander, E., Mohs, R. C. and Davis, K. L. : Cholinergic approaches to the treatment of Alzheimer's disease. Br. Med. Bull. 142, 97 (1986)